Abstract:STUDY QUESTION Does intrauterine infusion of granulocyte colony-stimulating factor (G-CSF) prevent adhesion reformation and promote endometrial growth after hysteroscopic adhesiolysis? SUMMARY ANSWER Intrauterine perfusion of G-CSF can increase endometrial thickness but does not prevent the recurrence of intrauterine adhesions (IUAs) in patients with Asherman syndrome (AS) after surgery. WHAT IS KNOWN ALREADY Intrauterine infusion of G-CSF has been used in attempts to treat patients with recurrent miscarriage and an idiopathic thin endometrium for either fresh or frozen-thawed embryo transfer cycles but without uniform efficacy. There have been no reports on the effect of G-CSF on the recurrence of IUAs, endometrial regrowth or pregnancy results in specific populations with AS. STUDY DESIGN, SIZE, DURATION This two-center prospective double-blind randomized controlled trial ran between April 2016 and August 2021. In it, 245 patients with moderate to severe AS were randomized to G-CSF and control groups at a 1:1 ratio; 229 women were included in the adhesion recurrence analysis; and 164 patients were analyzed for pregnancy outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS All eligible patients received the first hysteroscopic adhesion separation and balloon placement procedure. Patients who met our inclusion and exclusion criteria were randomized after surgery. These patients returned for balloon removal and underwent intrauterine perfusion with 300 mu g (1.8 ml) G-CSF or 1.8 ml normal saline according to randomization at 7 days after surgery. A second-look hysteroscopy was carried out 1-2 months later. The primary outcome was the rate of formation of new adhesions at the second hysteroscopy. The secondary outcomes included endometrial thickness in the periovulatory period after surgery, as well as the clinical pregnancy and live birth rates. MAIN RESULTS AND THE ROLE OF CHANCE Age, menstrual cycle characteristics, pregnancy history and IUA score before surgery were similar between groups. There were no statistically significant differences in the adhesion reformation rate or median adhesion score reduction. However, G-CSF perfusion significantly improved endometrial thickness (7.91 +/- 2.12 mm vs 7.22 +/- 2.04 mm; P = 0.019, 95% CI for difference: -1.26 to -0.12), as well as cumulative pregnancy and live birth rate over time (P = 0.017 and P = 0.042). Furthermore, multivariate logistic regression analysis showed that postoperative endometrial thickness was an independent prognostic factor for pregnancy and live birth rates. LIMITATIONS, REASONS FOR CAUTION These results cannot be extended to older patients or those without AS, as our subjects had moderate or severe AS and were aged WIDER IMPLICATIONS OF THE FINDINGS Intrauterine perfusion of G-CSF could be an effective adjuvant therapy for patients with AS to increase endometrial thickness. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by grants from the National Key Research and Development Program of China (2018YFC1004800), the National Natural Science Foundation of China (82001624 and 81871209), the Natural Science Foundation of Zhejiang Province (LQ20H040004) and the provincial and ministerial construction project of Zhejiang Province (2017 WKJ-ZJ-1721). The authors declare that they have no conflicts of interest regarding this work. DATE OF FIRST PATIENT'S ENROLMENT 13 April 2016.

CSF1‐associated Decrease in Endometrial Macrophages May Contribute to Asherman's Syndrome

MicroRNA-122-5p Alleviates Endometrial Fibrosis Via Inhibiting the TGF-β/SMAD Pathway in Asherman's Syndrome.

Unresponsive thin endometrium caused by Asherman syndrome treated with umbilical cord mesenchymal stem cells on collagen scaffolds: a pilot study

Unresponsive Thin Endometrium Caused by Asherman Syndrome Treated With Umbilical Cord Mesenchymal Stem Cells: A Pilot Study

Granulocyte-macrophage Colony-Stimulating Factor Promotes Endometrial Repair after Injury by Regulating Macrophages in Mice.

Ankylosing Spondylitis Presenting with Macrophage Activation Syndrome

Endometrial stem cell-derived G-CSF attenuates endometrial fibrosis via Sonic Hedgehog transcriptional activator Gli2.

Vascular Endothelial Growth Factor 165 Inhibits Pro-Fibrotic Differentiation of Stromal Cells Via the DLL4/Notch4/smad7 Pathway.

Intrauterine administration of G-CSF for promoting endometrial growth after hysteroscopic adhesiolysis: a randomized controlled trial

Understanding of Cytokines and Targeted Therapy in Macrophage Activation Syndrome.

Autocrine Production of Interleukin-34 Promotes the Development of Endometriosis Through CSF1R/JAK3/STAT6 Signaling

Stem Cell-Based Therapy for Asherman Syndrome: Promises and Challenges

LAMB3 Promotes Myofibrogenesis and Cytoskeletal Reorganization in Endometrial Stromal Cells via the RhoA/ROCK1/MYL9 Pathway

CSF-1-Induced DC-SIGN+ Macrophages Work In The Ovarian Endometriosis

Transplantation of Collagen Scaffold with Autologous Bone Marrow Mononuclear Cells Promotes Functional Endometrium Reconstruction Via Downregulating ΔNp63 Expression in Asherman’s Syndrome

Genetic and Pharmacological Targeting of GSDMD Ameliorates Systemic Inflammation in Macrophage Activation Syndrome

Cross-talk Between Macrophages and Atrial Myocytes in Atrial Fibrillation

Exosomes from the Uterine Cavity Mediate Immune Dysregulation via Inhibiting the JNK Signal Pathway in Endometriosis

Abstract PR566

IL-4-induced M2 macrophages inhibit fibrosis of endometrial stromal cells

Follicle-Stimulating Hormone Provokes Macrophages to Secrete IL-1β Contributing to Atherosclerosis Progression.